Skip to main content

Table 2 Univariate analysis of locoregional control (LRC)

From: Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

 

At 1 year (%)

At 3 years (%)

P

Radiochemotherapy regimen

 Cisplatin weekly (N = 75)

70

58

 

 Cisplatin 100 mg/m2 (N = 58)

85

78

0.010

Age

 ≤56 years (N = 67)

78

65

 

 ≥57 years (N = 66)

74

68

0.72

Gender

 Female (N = 29)

92

87

 

 Male (N = 104)

72

61

0.010

ECOG Performance score

 0–1 (N = 115)

78

69

 

 2 (N = 18)

66

49

0.14

Primary tumor site

 Oropharynx (N = 69)

83

74

 

 Hypopharynx (N = 19)

47

47

 

 Larynx (N = 30)

79

67

 

 Oral cavity/Floor of mouth (N = 15)

75

56

0.047

T-category

 T1–2 (N = 16)

93

76

 

 T3–4 (N = 117)

74

65

0.28

N-category

 N0-2a (N = 66)

76

68

 

 N2b-3 (N = 67)

76

65

0.93

Histologic grading

 G 1–2 (N = 85)

77

69

 

 G3 (N = 48)

75

63

0.65

Cumulative cisplatin dose

 ≤200 mg/m2 (N = 85)

70

62

 

 >200 mg/m2 (N = 48)

86

74

0.09

  1. After Bonferroni correction for multiple tests, p-values of <0.006 were considered significant